Immunopotentiation by Lymph-Node Targeting of a Malaria Transmission-Blocking Nanovaccine

Keyphrases

• Malaria Transmission Blocking 100%
• Nanovaccine 100%
• Lymph Node Targeting 100%
• Immunopotentiating Activity 100%
• Specific Antibodies 66%
• Biodegradable Nanoparticles 66%
• Antibody Titer 66%
• Antigen-specific Antibody 66%
• Transmission-blocking Vaccine 66%
• Mosquito Midgut 66%
• Evolutionarily Conserved 33%
• Vaccine Delivery System 33%
• Further Development 33%
• CpG ODN 33%
• Ovalbumin 33%
• Blood Meal 33%
• Antigen-specific 33%
• Nanoparticle Vaccine 33%
• Malaria 33%
• Human Infection 33%
• Size Control 33%
• Healthcare Infrastructure 33%
• Dose Sparing 33%
• Serum IgE 33%
• Vaccine Target 33%
• Co-delivery 33%
• Abrogation 33%
• Nanoparticle Delivery System 33%
• Specific Immune Response 33%
• Model Antigen 33%
• Aminopeptidase N 33%
• Direct Membrane Feeding Assay 33%
• Immunostimulatory Sequences 33%
• Malaria Vaccine 33%
• Antigen Dose 33%
• Neutralizing Epitope 33%
• Traversal 33%
• Parasite Transmission 33%
• Malaria Mosquito 33%
• De-facto 33%
• Target Lymph Node 33%
• Anopheline 33%
• Transmission Reducing Activity 33%

Medicine and Dentistry

• Lymph Node 100%
• Malaria 100%
• Immunopotentiation 100%
• Nanovaccine 100%
• Alanine Aminopeptidase 66%
• Antibody Response 66%
• Antibodies 66%
• Midgut 66%
• Nanoparticle 66%
• Infection 33%
• Immune Response 33%
• Epitope 33%
• Ingestion 33%
• Antigen Specificity 33%
• CpG Oligodeoxynucleotide 33%
• Antigen 33%
• Ovalbumin 33%
• Parasite Transmission 33%

Immunology and Microbiology

• Lymph Node 100%
• Immunopotentiation 100%
• Antibody Response 66%
• Antibody Titer 66%
• Microsomal Aminopeptidase 66%
• Midgut 66%
• Antibodies 66%
• Immune Response 33%
• Epitope 33%
• Ingestion 33%
• Antigen Specificity 33%
• Antigen 33%
• CpG Oligodeoxynucleotide 33%
• Parasite Transmission 33%
• Immunology 33%